TAGAMET
LOE ApproachingNDAORALTABLETPriority Review
Approved
Aug 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAGAMET is an oral small-molecule tablet approved in 1977 by GSK. The specific mechanism of action and indications are not provided in available data, but the drug represents a mature, established therapeutic option. This is a legacy product with a long market history.
LOE Approaching
As LOE approaches, the brand team is likely contracting; career growth opportunities are limited unless involved in transition or line-extension strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TAGAMET offers limited career growth in a sunset phase; roles focus on managing decline, supporting generic transitions, or defending remaining market share. This is a stabilization/maintenance position rather than a growth opportunity.
Brand ManagerMarket Access Manager
Worked on TAGAMET at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.